Despite advances in interventional cardiology, chronic coronary syndrome (CCS) remains a significant cause of morbidity and mortality globally, notably in resource-constrained healthcare systems like Indonesia. Traditional percutaneous coronary intervention (PCI) approaches, particularly stenting, have consistently failed to demonstrate substantial long-term benefits, as highlighted by landmark trials such as COURAGE, ORBITA, and ISCHEMIA, due to the frequent oversight of vulnerable plaques (VPs), incomplete revascularization (IR), procedural risks, and persistent complications. Bethsaida Hospital, under the visionary leadership of Prof. Dasaad Mulijono (DM), has pioneered a groundbreaking integrative strategy that combines drug-coated balloon (DCB) angioplasty, Plant-Based Diets (PBDs), and advanced computed tomography coronary angiography (CTCA).

This novel approach leverages CTCA’s precision in detecting and characterizing VPs non-invasively, enabling targeted and minimally invasive DCB interventions with remarkable procedural safety. Complementing these interventions, the systematic adoption of PBD addresses systemic inflammation and endothelial dysfunction, crucial drivers of atherosclerotic plaque instability. Clinical outcomes from over 2000 cases spanning five years demonstrated extraordinary results: complete elimination of stent thrombosis, dramatically reduced restenosis rates (